<DOC>
	<DOC>NCT02116361</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of onabotulinumtoxinA (BOTOXÂ®) compared with placebo as treatment for major depressive disorder (MDD) in adult females.</brief_summary>
	<brief_title>OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Moderate to severe major depressive disorder Prior treatment with botulinum toxin of any serotype for any reason Use of antidepressant medication for depression within 2 weeks of study Diagnosis of Myasthenia gravis, EatonLambert Syndrome, Amyotrophic Lateral Sclerosis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>